The global medico-regulatory affairs outsourcing market was valued at $ 1.9 billion in 2014 and is expected to reach $ 5.7 billion by 2023, at a CAGR of 11.5 percent during the forecast period from 2015 to 2023 (Source - Transparency Market Research forecast 2015-2023). In recent years innovator companies are increasingly relying on the CROs not only for clinical trials but for other specialized activities in drug development process. Biopharmaceutical companies are now outsourcing their medico-regulatory requirements in order to access new capabilities of CROs, focusing on core competencies and variable costs. As most of the global CROs established their operations...
Dhileep Krishnamurthy, Piramal
Ravindra Kumar Pandey, Sr. Vice President, Alembic
Jawaid Imam, Associate VP(Works), Aristo
Smita Saha, Vice President-HR, AstraZeneca
Prashant Pathak, CEO & MD, Delcure
Anil Joshi, CEO, GCV Life
Gaurav N. Brahmbhatt, Head - Pharma Business, Health Care
Chandan Mishra, Regional Manager East, Roche
Mahesh Kalsekar,Director - Business Operations &Strategy,Takeda Pharmaceuticals India
Bipin Joshi, Head, Systems & IT, Rockland Hospital
Saptarshi Nath, MD & Co-Founder, Overcart